| $687M | ||
| $385M | ||
| $215M | ||
| $100M | ||
| $87M | ||
| $82M |
Buys | $300,760 | 1 | 33 |
Sells | $9,806,982 | 2 | 67 |
| Madaus Martin D | director | 1 | $300,760 | 0 | $0 | $300,760 |
| Stamoulis Christiana | director | 0 | $0 | 1 | $540,864 | $-540,864 |
| MACMILLAN STEPHEN P | Chairman, President and CEO | 0 | $0 | 1 | $9.27M | $-9.27M |
Hologic, Inc. develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment in the United States, Europe, the Asia-Pacific, and internationally. It operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. The company provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load tests for HIV, Hepatitis C, and Hepatitis B; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays for the detection of SARS-CoV-2; ThinPrep System for use in cytology applications; Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth; and various diagnostic tests for the detection of Group B Streptococcus. It also offers breast imaging and analytics, such as 2D and 3D digital mammography systems and reading workstations, minimally invasive breast biopsy guidance systems and devices, breast biopsy site markers and localization, specimen radiology, and ultrasound and connectivity solutions; and breast conserving surgery products. In addition, the company provides NovaSure Endometrial Ablation System for the treatment of abnormal uterine bleeding; MyoSure Hysteroscopic Tissue Removal System for the removal of fibroids, polyps, and other pathology within the uterus; and Fluent Fluid Management System that provides liquid distention during diagnostic and operative hysteroscopic procedures. Further, it offers Horizon DXA, a dual energy X-ray system; and the Fluoroscan Insight FD mini C-arm to perform minimally invasive orthopedic surgical procedures. The company sells its products through direct sales and service forces, and independent distributors and sales representatives. Hologic, Inc. was incorporated in 1985 and is headquartered in Marlborough, Massachusetts.
Over the last 12 months, insiders at Hologic, Inc. have bought $300,760 and sold $9.81M worth of Hologic, Inc. stock.
On average, over the past 5 years, insiders at Hologic, Inc. have bought $300,760 and sold $10.23M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Madaus Martin D (director) — $300,760.
The last purchase of 5,445 shares for transaction amount of $300,760 was made by Madaus Martin D (director) on 2025‑05‑07.
| 2025-10-20 | Sale | Stamoulis Christiana | director | 7,402 0.0034% | $73.07 | $540,864 | +3.28% | |
| 2025-09-22 | Sale | MACMILLAN STEPHEN P | Chairman, President and CEO | 138,358 0.0619% | $66.97 | $9.27M | +10.06% | |
| 2025-05-07 | Madaus Martin D | director | 5,445 0.0024% | $55.24 | $300,760 | +20.60% | ||
| 2024-12-04 | Sale | Mitchell Essex D | Chief Operating Officer | 24,856 0.0109% | $76.34 | $1.9M | -13.92% | |
| 2024-08-29 | Sale | Oberton Karleen Marie | Chief Financial Officer | 52,679 0.0226% | $80.56 | $4.24M | -17.03% | |
| 2024-08-06 | Sale | Schnittker Brandon | Div. President, GYN Surgical | 476 0.0002% | $83.11 | $39,559 | -17.13% | |
| 2024-08-01 | Sale | COHN BENJAMIN JORDAN | Principal Accounting Officer | 5,093 0.0022% | $81.99 | $417,570 | -15.76% | |
| 2024-07-30 | Sale | MACMILLAN STEPHEN P | Chairman, President and CEO | 44,039 0.0187% | $81.70 | $3.6M | -14.76% | |
| 2024-07-17 | Sale | MACMILLAN STEPHEN P | Chairman, President and CEO | 3,672 0.0016% | $80.13 | $294,223 | -9.15% | |
| 2024-07-17 | Sale | Stamoulis Christiana | director | 9,039 0.0039% | $79.50 | $718,601 | -9.15% | |
| 2024-03-14 | Sale | GARRETT SCOTT T | director | 16,441 0.0069% | $75.50 | $1.24M | +1.02% | |
| 2024-03-08 | Sale | CRAWFORD SALLY | director | 9,039 0.0038% | $76.40 | $690,607 | -1.08% | |
| 2024-03-08 | Sale | Dockendorff Charles J | director | 1,465 0.0006% | $76.21 | $111,648 | -1.08% | |
| 2024-01-29 | Sale | Oberton Karleen Marie | Chief Financial Officer | 14,940 0.0064% | $75.00 | $1.12M | +1.73% | |
| 2024-01-02 | Sale | Dockendorff Charles J | director | 16,017 0.0067% | $72.00 | $1.15M | +5.23% | |
| 2023-12-11 | Sale | GARRETT SCOTT T | director | 10,000 0.0042% | $68.71 | $687,116 | +11.02% | |
| 2023-11-29 | Sale | MACMILLAN STEPHEN P | Chairman, President and CEO | 47,711 0.0198% | $70.41 | $3.36M | +7.80% | |
| 2023-11-21 | Sale | Mitchell Essex D | Div. President, GYN Surgical | 7,500 0.0031% | $71.85 | $538,890 | +5.56% | |
| 2023-06-15 | Sale | GARRETT SCOTT T | director | 10,000 0.004% | $79.72 | $797,240 | -8.51% | |
| 2023-05-05 | Sale | Mitchell Essex D | Div. President, GYN Surgical | 2,390 0.001% | $83.73 | $200,115 | -10.59% |
| MACMILLAN STEPHEN P | Chairman, President and CEO | 1234624 0.5539% | $92.83M | 4 | 10 | +18.31% |
| Stamoulis Christiana | director | 47336 0.0212% | $3.56M | 0 | 6 | |
| Madaus Martin D | director | 5445 0.0024% | $409,382.33 | 1 | 0 | |
| ICAHN CARL C | 28154879 12.6309% | $2.12B | 0 | 1 | ||
| MUIR GLENN P | Executive VP and CFO | 815306 0.3658% | $61.3M | 1 | 55 | <0.0001% |
| CASCELLA ROBERT | CEO and President | 400655 0.1797% | $30.12M | 1 | 18 | <0.0001% |
| CUMMING JOHN W | Chairman | 305975 0.1373% | $23M | 1 | 16 | <0.0001% |
| Griffin John M. | General Counsel | 168944 0.0758% | $12.7M | 0 | 5 | |
| STEIN JAY A | Chief Technical Officer | 164608 0.0738% | $12.38M | 0 | 50 | |
| CRAWFORD SALLY | director | 132927 0.0596% | $9.99M | 0 | 20 | |
| SULLIVAN PATRICK J | Executive Chairman | 129874 0.0583% | $9.76M | 0 | 23 | |
| Oberton Karleen Marie | Chief Financial Officer | 84042 0.0377% | $6.32M | 0 | 24 | |
| Verstreken Jan | Group President, International | 64191 0.0288% | $4.83M | 0 | 1 | |
| MCDANIEL C WILLIAM | director | 63660 0.0286% | $4.79M | 1 | 0 | <0.0001% |
| Thornal Kevin R | Group Pres, Global Diagnostics | 62368 0.028% | $4.69M | 0 | 3 | |
| Valenti Peter J. III | Division Pres., Breast Health | 59991 0.0269% | $4.51M | 0 | 11 | |
| Harding David | SVP, International | 57169 0.0256% | $4.3M | 0 | 4 | |
| Mills Roger D. | GSVP & GM Service & Operations | 56960 0.0256% | $4.28M | 0 | 1 | |
| SOLTANI PETER | SVP & GM, Women's Health | 56704 0.0254% | $4.26M | 1 | 8 | +23.37% |
| LEAMING NANCY | director | 51779 0.0232% | $3.89M | 0 | 12 | |
| Daugherty Sean S. | Group President, BSH & Surg. | 49091 0.022% | $3.69M | 0 | 2 | |
| GARRETT SCOTT T | director | 48611 0.0218% | $3.65M | 0 | 3 | |
| Williamson Steve S | SVP, GYN Surgical | 41721 0.0187% | $3.14M | 0 | 7 | |
| WILSON WAYNE | director | 39215 0.0176% | $2.95M | 5 | 10 | <0.0001% |
| Doran Howard JR | SVP, Diagnostics Products | 38502 0.0173% | $2.89M | 2 | 2 | +2.9% |
| Bebo Allison P | SVP, Human Resources | 35680 0.016% | $2.68M | 0 | 3 | |
| Levy Lawrence M | director | 29437 0.0132% | $2.21M | 0 | 28 | |
| Mitchell Essex D | Chief Operating Officer | 27957 0.0125% | $2.1M | 0 | 3 | |
| Brady David J | SVP, Human Resources | 27749 0.0124% | $2.09M | 0 | 6 | |
| ULLIAN ELAINE | director | 23810 0.0107% | $1.79M | 1 | 13 | +28.03% |
| Casey Mark J | SVP, CAO, GC & Secretary | 14470 0.0065% | $1.09M | 0 | 10 | |
| LAVALLEE ROBERT H | SVP, Chief Accounting Officer | 11341 0.0051% | $852,673.09 | 0 | 16 | |
| COHN BENJAMIN JORDAN | Principal Accounting Officer | 10476 0.0047% | $787,638.06 | 0 | 17 | |
| Wendell Amy McBride | director | 10297 0.0046% | $774,179.95 | 1 | 0 | +4.92% |
| LAVANCE DAVID R JR | director | 9362 0.0042% | $703,881.97 | 0 | 17 | |
| Hellmann Elisabeth A | SVP, Human Resources | 8545 0.0038% | $642,455.83 | 0 | 1 | |
| Nawana Namal | director | 6954 0.0031% | $522,836.49 | 1 | 0 | +5.08% |
| LEVANGIE DANIEL J | director | 6334 0.0028% | $476,221.79 | 0 | 3 | |
| Schnittker Brandon | Div. President, GYN Surgical | 3735 0.0017% | $280,815.98 | 0 | 1 | |
| PEKARSKY JOHN R | SVP, Sales & Strategic Account | 1519 0.0007% | $114,206.02 | 0 | 7 | |
| Kingsley Stuart A | President, Surgical Division | 1452 0.0007% | $109,168.62 | 0 | 1 | |
| Dockendorff Charles J | director | 1572 0.0007% | $118,190.82 | 1 | 2 | +5.07% |
| Hastie Rohan | Group SVP & GM Diagnostics | 1500 0.0007% | $112,777.50 | 0 | 1 | |
| VON STETTEN ERIC | Vice President | 1254 0.0006% | $94,281.99 | 0 | 2 | |
| Compton Eric B. | COO | 795 0.0004% | $59,772.08 | 1 | 0 | +33.78% |
| PECK WILLIAM A | director | 0 0% | $0 | 0 | 1 | |
| KERSHAW PETER C | VICE PRESIDENT | 0 0% | $0 | 0 | 3 | |
| JACOBS IRWIN | director | 0 0% | $0 | 0 | 6 | |
| Lerner Arthur G | director | 0 0% | $0 | 0 | 3 | |
| Fajardo Laurie | director | 0 0% | $0 | 0 | 2 |
| Increased Positions | 369 | +46.89% | 18M | +8.1% |
| Decreased Positions | 334 | -42.44% | 20M | -9.21% |
| New Positions | 113 | New | 4M | New |
| Sold Out Positions | 60 | Sold Out | 1M | Sold Out |
| Total Postitions | 822 | +4.45% | 216M | -1.11% |
| Vanguard Group Inc | $1.97M | 11.76% | 26.21M | -587,955 | -2.19% | 2025-09-30 |
| T. Rowe Price Investment Management, Inc. | $1.62M | 9.66% | 21.55M | -3M | -10.52% | 2025-09-30 |
| Blackrock, Inc. | $1.46M | 8.71% | 19.41M | -527,670 | -2.65% | 2025-09-30 |
| Manufacturers Life Insurance Company, The | $783,784.00 | 4.69% | 10.45M | -572,007 | -5.19% | 2025-09-30 |
| State Street Corp | $748,258.00 | 4.47% | 9.98M | -122,097 | -1.21% | 2025-09-30 |
| Invesco Ltd. | $532,608.00 | 3.19% | 7.1M | -1M | -14.86% | 2025-09-30 |
| Geode Capital Management, Llc | $442,275.00 | 2.64% | 5.9M | +68,669 | +1.18% | 2025-09-30 |
| Victory Capital Management Inc | $410,253.00 | 2.45% | 5.47M | -28,864 | -0.53% | 2025-09-30 |
| Morgan Stanley | $293,420.00 | 1.75% | 3.91M | +2M | +65.77% | 2025-09-30 |
| Black Creek Investment Management Inc. | $280,751.00 | 1.68% | 3.74M | -284,484 | -7.06% | 2025-09-30 |